I believe it is well overdue. If they're so encouraged by the data meeting endpoints they decided to cut the trial short, it could have a few of the CDA's mouths watering. I know it'll take some time of course, but very much looking forward to see IPIX get a new presentation together. And seeing it taken into a small 2c trial before the big trial. Once the oral formulation is ready, we could see kevetrin's data and future in a journal. I think it makes it there sooner than later.

Quote:

---

Do you think the Kevetrin results will be published in a Medical Journal? Seems like a logical next step.

---